Pfizer presented detailed Phase III data for ritlecitinib (Litfulo) in nonsegmental vitiligo (NSV) at the 2026 European Academy of Dermatology and... New York City-based TriGemX Bio (formerly Kallyope ...
Litfulo Phase III results showed significant repigmentation in nonsegmental vitiligo, supporting planned regulatory filings.
TriGemX Bio raises $94 million to fund Phase III trials of oral migraine drug elismetrep. Discover the investors backing the program and what comes next.
Ubamatamab showed a 73% response rate and 11-month median progression-free survival in 11 LGSOC patients in an early-trial ...
Astrocyte Pharmaceuticals secures $9.5M Series B funding to advance AST-004 into Phase II trials for concussion and TBI ...
Foghorn Therapeutics is cutting about 40% of its workforce after ending FHD-909 and other SMARCA2 programs with Lilly. Read ...
Progentos begins Phase I/II human trial of oral PRO-1562 for multiple sclerosis remyelination. First-in-human study ...
Atara Biotherapeutics resubmits tabelecleucel BLA to FDA for EBV+ post-transplant lymphoproliferative disease. Latest updates ...
Regeneron and Sanofi expand antibody alliance with $1B upfront and $7B in milestones for IL-4/IL-13 pathway treatments. Learn ...
CMS finalized the mandatory GLOBE model, linking Medicare Part B rebates to international drug prices starting in 2027. See ...
Samsung Bioepis and Teva expanded their partnership to develop and commercialize up to six biosimilar candidates. See which ...
Pfizer's tilrekimig met the Phase II endpoint in atopic dermatitis, improving Week 16 EASI-75 responses across doses versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results